Participate in Research at CU Anschutz

The purpose of the study is to test the safety of the medicine called SGN-B7H4V alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.

The study will have 5 parts: Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the amount found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers. Part D will find out if and how much SGN-B7H4V can be given with pembrolizumab. Part E will use the amount found in Part D to find out how safe SGN-B7H4V with pembrolizumab is and if it works to treat triple negative breast cancer.